US FDA launches “PreCheck” pilot to speed up construction and review of domestic drug manufacturing plants, prioritising critical medicines and modern facility technology.

What happened

The U.S. Food and Drug Administration opened requests to join its PreCheck pilot program to boost US-based pharmaceutical manufacturing by speeding up facility build-outs and FDA review. The pilot uses a 2-phase approach: early FDA engagement during design and construction, then early feedback to optimise manufacturing and quality systems before approval.

Why it matters

If FDA review becomes more “front-loaded” and predictable, it can pull forward timelines for new and expanded US manufacturing capacity. That’s supportive for companies that build, equip, validate, and supply these facilities, while pressuring companies most de ...